In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViroCyt Inc.

Division of Sartorius Corp.
www.virocyt.com

Latest From ViroCyt Inc.

Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2017

Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.

Medical Device In Vitro Diagnostics

Deals In Depth: June/July 2016

Celgene and Novartis each signed $3 billion immuno-oncology deals, with Jounce and Xencor, respectively; Galenica Group made a $1.5 billion acquisition for a hyperkalaemia drug. Public financings grew from May to July in the biopharma industry, but decreased month over month in the device sector.

Deals BioPharmaceutical

Deals Shaping the Medical Industry, August 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in July 2016.

Market Intelligence Deals

Venture Funding Deals, September 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced July through August 2015.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • ViroCyt LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sartorius Corp.
  • Senior Management
  • Robert Kline, Pres. & CEO
    Michael Olszowy, CTO
    Michael Artinger, VP, Mktg. & Strategic Partnering
    Greg Krueger, VP, Global Sales
  • Contact Info
  • ViroCyt Inc.
    Phone: (720) 599-3700
    100 Technology Dr., Ste. 325
    Broomfield, CO 80021
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register